15-12G - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

Guggenheim downgraded ImmunoGen from Buy to Neutral and set a new price target of $31.00 from $25.00 previously

Goldman initiated coverage of ImmunoGen with a rating of Neutral and set a new price target of $17.00

Deutsche Bank initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $25.00

Oppenheimer initiated coverage of ImmunoGen with a rating of Perform and set a new price target of $16.00

Piper Sandler upgraded ImmunoGen from Neutral to Overweight and set a new price target of $16.00 from $6.00 previously

Truist initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $10.00

Barclays initiated coverage of ImmunoGen with a rating of Overweight and set a new price target of $8.00

RBC Capital Mkts downgraded Immunogen from Outperform to Sector Perform and set a new price target of $6.00 from $9.00 previously

SVB Leerink reiterated coverage of Immunogen with a rating of Market Perform and set a new price target of $5.00 from $7.00 previously

BMO Capital initiated coverage of Immunogen with a rating of Outperform

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancerELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancerImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignanciesTransaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billionAbbVie to hold an investor conference call at 8:00 a.m. CTNORTH CHICAGO

Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024 Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer Conference Call to be Held at 8:00 a.m. E

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN

Continued Strong Momentum with ELAHERE Launch in US; Net Sales of $77.4 Million in Q2 Presented Positive Results for ELAHERE from Phase 3 MIRASOL Trial During Late-Breaking Oral Presentation at ASCO; First Therapy to Demonstrate an Overall Survival Benefit Compared to Chemotherapy in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Submission of ELAHERE MAA to Support Expansion into Europe and sBLA for Potential Full Approval in US on Track for Q4 2023 Presented Interim Analysis from Phase 2 CADENZA Trial at EHA Congress Showing Encouraging Anti-Tumor Activity and Durable Responses for Pivekimab Sunirine in BPDCN; Pivotal Frontline Cohort Now Fully Enrolled Generated $350.8 Mill

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGe

Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in Europe and sBLA in US Anticipated in H2 2023 Conference Call to be Held at 8:00 AM ET Today ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-po

Strong Adoption of ELAHERE; Net Sales of $29.5 Million in First Full Quarter of Launch Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Early May; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Announced Non-Dilutive Financing for Up to $175 Million to Strengthen Balance Sheet and Support Company's Growth Trajectory Expanded Leadership Team with the Appointment of Isabel Kalofonos as Senior Vice President and Chief Commercial Officer Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent prog

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN Immu

Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2 2023; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Encouraging Safety and Efficacy Data from Pivekimab Sunirine Triplet in AML Presented in Oral Session at ASH 2022; Clinical Collaboration with Gilead Announced to Evaluate Pivekimab with Magrolimab in Relapsed/Refractory AML Announced a Global, Multi-Target License and Option Agreement of ImmunoGen's ADC Tech

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGen is developin

For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

Submission status for IMMUNOGEN INC's drug MIRVETUXIMAB SORAVTANSINE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

ImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen's Senior Vice President and Chief Financial Officer, the compensation committee of the Company's Board of Directors (the "Compensation Committee") approved grants of non-qualified stock options to purchase 295,975 shares of its common stock and restricted stock units ("RSUs") covering 51,625 shares of its common stock under the Inducement Plan to Ms. White. The Inducement Plan is used exclusively for the grant of equity awards t

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer. "We are excited to have Lauren join our team and believe that her expertise in financial planning and strategy, operations, and investor relations will be invaluable as we evolve as a fully-integrated oncology company," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "We have made significant progress in the business this year with the successful launch of ELAHERE®, the positive MIRASOL results intended to support ELAHERE's expansion into Eu

ImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the previously announced appointment of Isabel Kalofonos as ImmunoGen's Chief Commercial Officer, the compensation committee of the Company's Board of Directors (the "Compensation Committee") approved, effective as of April 28, 2023, grants of a non-qualified stock option to purchase 284,250 shares of its common stock (the "Kalofonos Options") and restricted stock units ("RSUs") covering 47,375 shares of its common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the "Inducement Plan"). In addit

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer. "We are excited to welcome Isabel to ImmunoGen's Executive Committee to lead our best-in-class commercial organization at this important moment for the company. Since the approval of ELAHERE® (mirvetuximab soravtansine-gynx) in late November for platinum-resistant ovarian cancer, we have made significant progress with the launch, highlighted by the breadth and depth of adoption, strong demand for FRα testing, and favorable market access coverage," said Mark

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 29, 2022, and in connection with the previously announced appointment of Michael J. Vasconcelles, MD as ImmunoGen's Executive Vice President, Research, Development, and Medical Affairs, the compensation committee of the Company's Board of Directors (the "Compensation Committee") approved grants of non-qualified stock option awards to purchase 960,000 shares of its common stock (the "Vasconcelles Options") under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the "Inducement Plan"). In addition, ImmunoGen announced

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs. "Following the recent approval and launch of ELAHERE™ (mirvetuximab soravtansine-gynx), we have transitioned to a fully-integrated oncology company pursuing the global development and commercialization of our portfolio of novel ADCs. As we look to expand ELAHERE's label and advance our pipeline, it is essential that we strategically align our research, development, clinical, medical, and regulatory affairs activities at a local, re

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2022, the compensation committee of the Company's Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 328,050 shares of its common stock (the "Employee Options") to ten new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the "Inducement Plan"). In addition, ImmunoGen announced that in connection with the previously announced appointment of Daniel S. Char as ImmunoGen's Senior Vice President and Chief Legal Officer, the compensation committee of Imm

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Daniel Char, JD, has been appointed Senior Vice President and Chief Legal Officer. "We are pleased to welcome Daniel to ImmunoGen to lead our Legal team and join ImmunoGen's Executive Committee. With his deep expertise advising on commercial, regulatory, compliance, and corporate governance matters, Daniel will play an important role as we increase the scale and complexity of the business as we build momentum with the launch of ELAHERE™ (mirvetuximab soravtansine-gynx) and advance the rest of our portfolio," said Mark Enyedy, ImmunoGen's Presid

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)

4 - ImmunoGen, Inc. (0000855654) (Issuer)